Stock MYID REKLAIM LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Reklaim Ltd.

Equities

MYID

CA7594021007

Market Closed - Toronto S.E.
Other stock markets
 10:08:56 28/06/2024 pm IST 		5-day change 1st Jan Change
0.09 CAD -18.18% Intraday chart for Reklaim Ltd. -.--% -.--%
30/05 Reklaim Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
24/04 Reklaim Cuts Debt by $100,000 Following Warrant Exercise MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Reklaim Ltd. Reports Strong Q1 2024 Results: Higher Margins and Increased Cash Flow
PR
Reklaim Ltd. Reports Strong Q1 2024 Results: Higher Margins and Increased Cash Flow
AQ
Reklaim : Management’s Discussion & Analysis 1Q24
PU
Reklaim : Interim Financial Statements 1Q24 - Consolidated
PU
Reklaim : Corporate Presentation
PU
Reklaim Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Reklaim : Corporate Presentation
PU
Reklaim Cuts Debt by $100,000 Following Warrant Exercise
MT
Reklaim Ltd. Reduces Debt Following Successful Warrant Exercises
PR
Reklaim Ltd. Reduces Debt Following Successful Warrant Exercises
AQ
Reklaim Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
REKLAIM LTD Announces Q4 & 2023 Outcomes: Achieving Profitability with $872K in Profit and a 74% Surge in Annual Revenue
PR
REKLAIM LTD Announces Q4 & 2023 Outcomes: Achieving Profitability with $872K in Profit and a 74% Surge in Annual Revenue
AQ
Forge Biologics Novel AAV Gene Therapy FBX-101 for Patients with Krabbe Disease is granted UK's Innovation Passport Designation
AQ
Reklaim Expects to Report Profitable Guidance for Fiscal 2023
MT
Reklaim Ltd Unveils Profitable Guidance for Fiscal 2023
PR
Reklaim Ltd Unveils Profitable Guidance for Fiscal 2023
AQ
Forge Biologics Announces Positive FBX-101 Clinical Trial Update in Patients with Krabbe Disease Identified by Newborn Screening Ahead of RUSP Vote
AQ
Transcript : Reklaim Ltd., Q3 2023 Earnings Call, Nov 09, 2023
Reklaim Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MYID Stock
  4. News Reklaim Ltd.